Table 1 Proportion of ICU physicians estimating the different potential indications of high-flow nasal cannula therapy as “good” or “very good”
From: High-flow nasal cannula therapy: clinical practice in intensive care units
Overall, % (n) | Seniors, % (n) | Juniors, % (n) | p* | |
|---|---|---|---|---|
Hypoxemic ARF | 100 (111/111) | 100 (68/68) | 100 (43/43) | 1 |
Pneumonia | 98 (109/111) | 97 (66/68) | 100 (43/43) | 0.52 |
Thoracic trauma | 91 (100/110) | 90 (60/67) | 93 (40/43) | 0.74 |
Pulmonary embolism | 85 (94/110) | 87 (58/67) | 84 (36/43) | 0.78 |
ARDS | 71 (78/110) | 67 (45/67) | 77 (33/43) | 0.39 |
Acute pulmonary edema | 57 (63/111) | 74 (50/68) | 30 (13/43) | < 0.0001 |
Acute severe asthma | 40 (44/109) | 45 (30/67) | 33 (14/42) | 0.32 |
“Do not intubate” patients | 92 (100/109) | 90 (60/67) | 95 (40/42) | 0.48 |
Per bronchoscopy | 92 (97/106) | 91 (58/64) | 93 (39/42) | 1 |
Preoxygenation before ETI | 84 (86/102) | 81 (51/63) | 90 (35/39) | 0.28 |
Post-operative ARF | 76 (80/105) | 77 (50/65) | 75 (30/40) | 0.82 |
Post-extubation ARF treatment | 70 (74/105) | 70 (45/64) | 71 (29/41) | 1 |
Post-extubation ARF prevention | 44 (39/89) | 45 (25/56) | 42 (14/33) | 1 |
Hypercapnic ARF | 33 (27/83) | 29 (15/52) | 39 (12/31) | 0.47 |
Bronchial dilatation | 32 (35/108) | 27 (18/67) | 41 (17/41) | 0.14 |
Thoracic wall deformity | 32 (35/111) | 30 (19/68) | 37 (16/43) | 0.40 |
COPD exacerbation | 28 (31/110) | 22 (15/67) | 37 (16/43) | 0.13 |
Acute pulmonary edema | 25 (28/111) | 31 (21/68) | 16 (7/43) | 0.12 |
Neuromuscular disease | 20 (22/111) | 19 (13/68) | 21 (9/43) | 0.81 |
Obesity hypoventilation syndrome | 19 (21/111) | 16 (11/68) | 23 (10/43) | 0.46 |
Acute severe asthma | 14 (15/111) | 15 (10/68) | 12 (5/43) | 0.78 |
Obstructive sleep apnea syndrome | 7 (8/110) | 6 (4/67) | 9 (4/43) | 0.71 |